
Contents

Preface	v
Contributors	xi
1 Introduction to the Background, Principles, and State of the Art in Suicide Gene Therapy Ion Niculescu-Duvaz and Caroline J. Springer	1
2 Introduction to Vectors for Suicide Gene Therapy Caroline J. Springer	29
3 Construction of VNP20009: A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-Targeting Salmonella for Parenteral Administration in Humans Kenneth Brooks Low, Martina Ittensohn, Xiang Luo, Li-Mou Zheng, Ivan King, John M. Pawelek, and David Bermudes	47
4 Nonreplicating DNA Viral Vectors for Suicide Gene Therapy: The Adenoviral Vectors Masato Yamamoto and David T. Curiel	61
5 Replication-Selective Oncolytic Adenoviruses Gunnel Halldén, Stephen H. Thorne, Jingping Yang, and David H. Kirn	71
6 Retroviral Vectors for Suicide Gene Therapy Colin Porter	91
7 Nonviral Liposomes Andrew D. Miller	107
8 Peptide- and Polymer-Based Gene Delivery Vehicles Richard Brokx and Jean Gariépy	139
9 Design of Prodrugs for Suicide Gene Therapy Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, and Caroline J. Springer	161
10 Cytochrome P450-Based Gene Therapies for Cancer E. Antonio Chiocca and David J. Waxman	203
11 Tumor Sensitization to Purine Analogs by <i>E. coli</i> PNP Kimberly V. Curlee, William B. Parker, and Eric J. Sorscher	223
12 Enzyme–Prodrug Systems: Carboxylesterase/CPT-11 Mary K. Danks and Philip M. Potter	247

13	Enzyme–Prodrug Systems: <i>Thymidine Phosphorylase/5'-Deoxy-5-Fluorouridine</i> Alexandre Evrard, Joseph Ciccolini, Pierre Cuq, and Jean-Paul Cano	263
14	Methods to Improve Efficacy in Suicide Gene Therapy Approaches: <i>Targeting Prodrug-Activating Enzymes Carboxypeptidase G2 and Nitroreductase to Different Subcellular Compartments</i> Silke Schepelmann, Robert Spooner, Frank Friedlos, and Richard Marais.....	279
15	Extracellular β -Glucuronidase for Gene-Directed Enzyme–Prodrug Therapy Sabine Brüsselbach	303
16	Enhancement of Suicide Gene Prodrug Activation by Random Mutagenesis Jean-Emmanuel Kurtz and Margaret E. Black	331
17	Combination Suicide Gene Therapy Wolfgang Uckert, Brian Salmons, Christian Beltinger, Walter H. Günzburg, and Thomas Kammertöns	345
18	Immune Response to Suicide Gene Therapy Shigeki Kuriyama, Hirohisa Tsujinoue, and Hitoshi Yoshiji	353
19	Targeting Cancer With Gene Therapy Using Hypoxia as a Stimulus Gabi U. Dachs, Olga Greco, and Gillian M. Tozer	371
20	Radiation-Activated Antitumor Vectors Simon D. Scott and Brian Marples	389
21	In Vitro and In Vivo Models for the Evaluation of GDEPT: <i>Quantifying Bystander Killing in Cell Cultures and Tumors</i> William R. Wilson, Susan M. Pullen, Alison Hogg, Stephen M. Hobbs, Frederik B. Pruijn, and Kevin O. Hicks	403
22	Suicide Gene Therapy in Liver Tumors Long R. Jiao, Roman Havlik, Joanna Nicholls, Steen Lindkaer Jensen, and Nagy A. Habib	433
23	Clinical Trials With GDEPT: <i>Cytosine Deaminase and 5-Fluorocytosine</i> Nicola L. Brown and Nicholas R. Lemoine	451
24	The Nitroreductase/CB1954 Enzyme–Prodrug System Nicola K. Green, David J. Kerr, Vivien Mautner, Peter A. Harris, and Peter F. Searle	459

25	Side Effects of Suicide Gene Therapy <i>Marjolijn M. van der Eb, Bertie de Leeuw, Alex J. van der Eb, and Rob C. Hoeben</i>	479
26	Antibody-Directed Enzyme–Prodrug Therapy <i>R. Barbara Pedley, Surinder K. Sharma, Robert E. Hawkins, and Kerry A. Chester</i>	491
27	Bioreductive Prodrugs for Cancer Therapy <i>Beatrice Seddon, Lloyd R. Kelland, and Paul Workman</i>	515
	Index	543